Enamptcumab is under clinical development by Aqualung Therapeutics and currently in Phase II for Acute Respiratory Distress Syndrome. According to GlobalData, Phase II drugs for Acute Respiratory Distress Syndrome have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Enamptcumab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Enamptcumab overview

Enamptcumab is under development for the prevention and treatment of acute respiratory distress syndrome, acute lung injury, ventilator-induced lung injury, radiation induced lung injury, idiopathic pulmonary fibrosis, inflammatory bowel diseases, NASH, systemic lupus vasculitis/DAH and prostate cancer, fibrosis of cardiac (post ischemic), Chorioamnionitis and pulmonary arterial hypertension. The drug candidate is administered through intravenous route. The drug candidate is humanized monoclonal antibody acts by targeting nicotinamide phosphoribosyl transferase (NAMPT).

Aqualung Therapeutics overview

Aqualung Therapeutics, is developing a novel, anti-inflammatory monoclonal antibody strategy to treat serious unchecked inflammation. The company is headquartered in United States.

For a complete picture of Enamptcumab’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 1 April 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.